Fintel reports that on December 16, 2025, Needham maintained coverage of SI-BONE (NasdaqGM:SIBN) with a Buy recommendation.

Needham analyst David Saxon raised the firm’s price target on SI-Bone (SIBN) to $27 from $24 and keeps a Buy rating on the shares. The firm has ...

SI-BONE, Inc., a company focused on medical technologies for sacropelvic disorders, announced it will release its financial results for the fourth quarter and full year of 2024 on February 24, 2025, ...

The medical device maker posted a satisfying beat-and-raise third quarter. During the period, it managed to narrow its net loss considerably. SI-Bone took the wraps off its third-quarter numbers just ...

New positive coverage policy further validates acceptance of iFuse as an important treatment option for patients with chronic sacroiliac joint dysfunction SANTA CLARA, Calif., May 29, 2020 (GLOBE ...

SI-BONE reports strong revenue growth and improved financial metrics for Q4 2024 and FY 2024, achieving positive adjusted EBITDA. SI-BONE, Inc. reported strong financial results for the fourth quarter ...

SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be ...

Today, we take a look at SI-BONE, Inc., a medical device company focused on developing implantable devices for musculoskeletal disorders. The company is targeting a large potential market, delivers ...

Over 1,400 active U.S. physicians with 300 physicians added in the quarter, representing 27.3% growth CMS FY 2026 proposed hospital inpatient rule for New Technology Add-On Payment (“NTAP”) effective ...

The current share price of $18.60 indicates SI-BONE is trading slightly above its Fair Value based on InvestingPro analysis. Following the transactions, Pisetsky directly owns 251,896 shares of ...

Si-Bone makes the iFuse Implant System for the sacroiliac joint, found in the lower back. The company said it increased its surgeon base to 950 surgeons in the U.S. Revenue for Si-Bone was up 46% year ...